Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Raw Materials (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Raw Materials for 7 consecutive years, with $628000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Raw Materials fell 12.78% year-over-year to $628000.0, compared with a TTM value of $628000.0 through Dec 2025, down 12.78%, and an annual FY2025 reading of $628000.0, down 12.78% over the prior year.
  • Raw Materials was $628000.0 for Q4 2025 at Karyopharm Therapeutics, roughly flat from $630000.0 in the prior quarter.
  • Across five years, Raw Materials topped out at $2.6 million in Q1 2022 and bottomed at $261000.0 in Q2 2022.
  • Average Raw Materials over 5 years is $1.0 million, with a median of $720000.0 recorded in 2024.
  • The sharpest move saw Raw Materials plummeted 85.7% in 2022, then soared 330.65% in 2023.
  • Year by year, Raw Materials stood at $1.8 million in 2021, then dropped by 23.76% to $1.4 million in 2022, then tumbled by 59.64% to $553000.0 in 2023, then skyrocketed by 30.2% to $720000.0 in 2024, then decreased by 12.78% to $628000.0 in 2025.
  • Business Quant data shows Raw Materials for KPTI at $628000.0 in Q4 2025, $630000.0 in Q3 2025, and $477000.0 in Q2 2025.